Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment
- 1 March 2019
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 559, 220-227
Abstract
No abstract availableKeywords
Funding Information
- Education, Audiovisual and Culture Executive Agency
- EuroNanoMed 3
- La Fondation Contre le Cancer (FAF-C/2016/830)
This publication has 37 references indexed in Scilit:
- Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical ModificationsMolecular Pharmaceutics, 2012
- nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic CancerCancer Discovery, 2012
- A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in ratsJournal of Neurosurgery, 2010
- Lipid nanocapsules: Ready-to-use nanovectors for the aerosol delivery of paclitaxelEuropean Journal of Pharmaceutics and Biopharmaceutics, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- A novel poloxamers/hyaluronic acid in situ forming hydrogel for drug delivery: Rheological, mucoadhesive and in vitro release propertiesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- Degradation of Paclitaxel and Related Compounds in Aqueous Solutions II: Nonepimerization Degradation Under Neutral to Basic pH ConditionsJournal of Pharmaceutical Sciences, 2008
- Mechanisms of Chemoresistance to Alkylating Agents in Malignant GliomaClinical Cancer Research, 2008
- In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxelInternational Journal of Pharmaceutics, 2007
- High-performance liquid chromatographic assay of taxolAnalytical Chemistry, 1992